Skip to contentF
Filana Therapeutics, Inc.
F
FLNAFilana Therapeutics, Inc. Q4 2016 · 10-K
Revenue—
Net Income-$2.52M-$2.52MN/M vs Q4 2015 EPS Diluted-$0.06-$0.06N/M vs Q4 2015 Operating Incomederived-$2,543,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Filana Therapeutics, Inc. · CIK 1069530 · Engraved from SEC EDGAR
Operating Cash Flowderived
Free Cash Flowderived-$3,030,000N/M ended Dec 31, 2016 · filed Mar 7, 2017 · 66 d after period end